• Applications
  • Infectious disease

    How it works
    When studying the immune response to infectious disease, established serological technologies, such as ELISA, only provide qualitative insights such as titer. MDS overcomes this challenge by enabling the measurement of both the affinity and the concentration of serum antibodies. This new type of quantitative serum-antibody profiling enables identification of high-affinity responders to infectious agents and correlation of affinity and concentration of antibodies with disease severity and clinical outcome.

    The study of antibodies is critical to understanding the immune response in health and disease, including the response to infection. However, accurately characterizing protein interactions in the complex, protein-rich environment of serum or plasma presents significant challenges. Traditional approaches to minimize background noise, such as dilution or blocking agents, can compromise reliability and applicability. The widely used ELISA can report only a simplistic antibody titer and is susceptible to non-specific surface binding and inter-laboratory variability. Our Seroaffinity and Concentration (SAffCon) Assay overcomes these challenges by directly measuring antibody affinity and calibration-free concentration in clinical samples, without the need for immobilization or purification. 

    In-solution advantages of MDS
    Fig 1. Comparison of serum antibody characterization using surface immobilization in ELISA vs. MDS.
    Case Study
    Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants.
    Get started

    To determine the affinity and the concentration of antibodies in serum, we recommend the following:

    Workflow specification and benefits:
    • 2-3 hours for data collection and analysis
    • KD range from nM to µM  
    • Concentration ranges from nM to µM 
    • Minimum sample volume is 60 µL 
    • 12 µl of sample per triplicate  
    • Quick & easy to perform 

    Could we support your research? Get in touch